Lipid-based Nanocarrier Drug Delivery Approach for Biomedical Application


Cite item

Full Text

Abstract

Abstract:The development of nanosized drug-carrier systems has been investigated over the past few decades using various techniques. The two main categories of these systems are polymeric nanoparticles and lipid nanoparticles (LNPs). The toxicological risk associated with lipid nanoparticles is significantly lower than the danger associated with polymeric nanoparticles due to the materials' natural and biological origins. Lipid-based drug delivery systems like Nanostructured lipid carriers (NLCs) and Solid Lipid Nanoparticles (SLNs) are well-established nanotechnology systems for preparing all major pharmaceuticals. These delivery systems can be scaled up with easy manufacturing procedures and are biocompatible. NLCs are the second generation of lipid-based nanocarriers (SLNs), formed by combining solid and liquid biocompatible lipids to form an unstructured matrix that provides high entrapment efficiency of active constituents. LNPs can promote the distribution of active pharmaceutical ingredients to the target site. Increasing the active drug concentration to target organ LNPs enhances the therapeutic effectiveness and reduces the side effects. This paper reviews the structure of SLNs and different NLCs, various steps involved in manufacturing lipid nanoparticles, excipients used in the formulation, and applications for targeted drug delivery.

About the authors

Prashant Upadhyay

School of Pharmaceutical Sciences, IFTM University

Author for correspondence.
Email: info@benthamscience.net

Ramsha Aslam

Faculty of Pharmacy, IFTM University

Email: info@benthamscience.net

Varsha Tiwari

Pharmacy Academy, IFTM University

Email: info@benthamscience.net

Sukirti Upadhyay

School of Pharmaceutical Sciences, IFTM University

Email: info@benthamscience.net

References

  1. Fang C-L, Al-Suwayeh SA, Fang J-Y. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol 2013; 7(1): 41-55. doi: 10.2174/187221013804484827 PMID: 22946628
  2. Basu B, Garala K, Bhalodia R, Joshi B, Mehta K. Solid lipid nanoparticles: A promising tool for drug delivery system. J Pharm Res 2010; 3: 84-92.
  3. Sharma A, Baldi A. Nanostructured lipid carriers: A review. J Dev Drugs 2018; 7: 1-12.
  4. Yadav P, Soni G, Mahor A, Alok S, Singh PP, Verma A. Solid lipid nanoparticles: An effective and promising drug delivery system-A review. Int J Pharm Sci Res 2014; 5: 1-16.
  5. Bagul US, Pisal VV, Solanki NV, Karnavat A. Current status of solid lipid nanoparticles: A review. Mod Appl Bioequivalence Bioavailab 2018; 3: 1-10.
  6. Uner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): Their benefits as colloidal drug carrier systems. Pharmazie 2006; 61(5): 375-86. PMID: 16724531
  7. Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol 2016; 44(1): 27-40. doi: 10.3109/21691401.2014.909822 PMID: 24813223
  8. Sarangi MK, Padhi S. Solid lipid nanoparticles–a review. J Crit Rev 2016; 5: 5-12.
  9. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application. Adv Pharm Bull 2015; 5(3): 305-13. doi: 10.15171/apb.2015.043 PMID: 26504751
  10. Swathi G, Prasanthi NL, Manikiran SS, Ramarao N. Solid lipid nanoparticles: Colloidal carrier systems for drug delivery. Int J Pharm Sci Res 2012; 43: 1-16.
  11. Radtke M, Müller RH. Nanostructured lipid carriers: A novel generation of solid lipid drug drug carriers. Pharm Technol Eur 1991; 17: 1-4.
  12. Mulla JS, Khazi IM, Jamakandi VG. Solid lipid nanoparticles: Potential applications. Indian J Nov Drug Deliv 2010; 2: 82-7.
  13. Shah R, Eldridge D, Palombo E, Harding I. Lipid Nanoparticles: Production, Characterization and Stability. Cham: Springer International Publishing 2015. doi: 10.1007/978-3-319-10711-0
  14. Thatipamula R, Palem C, Gannu R, Mudragada S, Yamsani M. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru 2011; 19(1): 23-32. PMID: 22615636
  15. Lima AM, Pizzol CD, Monteiro FBF, et al. Hypericin encapsulated in solid lipid nanoparticles: Phototoxicity and photodynamic efficiency. J Photochem Photobiol B 2013; 125: 146-54. doi: 10.1016/j.jphotobiol.2013.05.010 PMID: 23816959
  16. Rupenagunta A, Somasundaram I, Ravichandiram V, Kausalya J, Senthilnathan B. Solid lipid nanoparticles-A versatile carrier system. J Pharm Res 2011; 4: 2069-75.
  17. Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 1994; 30(1): 83-96. doi: 10.1016/0168-3659(94)90047-7
  18. Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules. Innov Food Sci Emerg Technol 2013; 19: 29-43. doi: 10.1016/j.ifset.2013.03.002
  19. Kumar S, Dilbaghi N, Saharan R, Bhanjana G. Nanotechnology as emerging tool for enhancing solubility of poorly water-soluble drugs. Bionanoscience 2012; 2(4): 227-50. doi: 10.1007/s12668-012-0060-7
  20. Jagdevappa P, Prashant G, Ravindra K, Sachin J, Satish M, Meghanath S. Applications of solid lipid nanoparticle in novel drug delivery system. Br Biomed Bull 2013; 1: 103-18.
  21. Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Deliv Sci Technol 2019; 51: 255-67. doi: 10.1016/j.jddst.2019.02.017
  22. zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism. Eur J Pharm Biopharm 1998; 45(2): 149-55. doi: 10.1016/S0939-6411(97)00150-1 PMID: 9704911
  23. Wissing SA, Müller RH. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity – in vivo study. Eur J Pharm Biopharm 2003; 56(1): 67-72. doi: 10.1016/S0939-6411(03)00040-7 PMID: 12837483
  24. Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 2011; 63(10-11): 901-8. doi: 10.1016/j.addr.2011.05.017 PMID: 21712055
  25. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56(9): 1257-72. doi: 10.1016/j.addr.2003.12.002 PMID: 15109768
  26. Geszke-Moritz M, Moritz M. Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies. Mater Sci Eng C 2016; 68: 982-94. doi: 10.1016/j.msec.2016.05.119 PMID: 27524099
  27. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54(S1): S131-55. doi: 10.1016/S0169-409X(02)00118-7 PMID: 12460720
  28. Hwang TL, Aljuffali IA, Hung CF, Chen CH, Fang JY. The impact of cationic solid lipid nanoparticles on human neutrophil activation and formation of neutrophil extracellular traps (NETs). Chem Biol Interact 2015; 235: 106-14. doi: 10.1016/j.cbi.2015.04.011 PMID: 25920576
  29. Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother 2018; 103: 598-613. doi: 10.1016/j.biopha.2018.04.055 PMID: 29677547
  30. Mehnert W, Mäder K. Solid lipid nanoparticles Production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2-3): 165-96. doi: 10.1016/S0169-409X(01)00105-3 PMID: 11311991
  31. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 2007; 59(6): 454-77. doi: 10.1016/j.addr.2007.04.011 PMID: 17570559
  32. Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008; 34(12): 1394-405. doi: 10.1080/03639040802130061 PMID: 18665980
  33. ALHaj NA. Abdullah R, Ibrahim S, Bustamam A. Tamoxifen drug loading solid lipid nanoparticles prepared by hot high pressure homogenization techniques. Am J Pharmacol Toxicol 2008; 3(3): 219-24. doi: 10.3844/ajptsp.2008.219.224
  34. Parhi R, Suresh P. Preparation and characterization of solid lipid nanoparticles-a review. Curr Drug Discov Technol 2012; 9(1): 2-16. doi: 10.2174/157016312799304552 PMID: 22235925
  35. Cortesi R, Esposjto E, Luca G, Nastruzzi C. Production of lipospheres as carriers for bioactive compounds. Biomaterials 2002; 23(11): 2283-94. doi: 10.1016/S0142-9612(01)00362-3 PMID: 12013175
  36. Puglia C, Blasi P, Rizza L, et al. Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. Int J Pharm 2008; 357(1-2): 295-304. doi: 10.1016/j.ijpharm.2008.01.045 PMID: 18343059
  37. Quintanar-Guerrero D, Tamayo-Esquivel D, Ganem-Quintanar A, Allémann E, Doelker E. Adaptation and optimization of the emulsification-diffusion technique to prepare lipidic nanospheres. Eur J Pharm Sci 2005; 26(2): 211-8. doi: 10.1016/j.ejps.2005.06.001 PMID: 16046105
  38. Kumar R. Lipid-based nanoparticles for drug-delivery systems. In: Mohapatra SS, Ranjan S, Dasgupta N, Mishra RK, Thomas S, Eds. Nanocarriers Drug Deliv. Elsevier 2019; pp. 249-84. doi: 10.1016/B978-0-12-814033-8.00008-4
  39. Giri TK. Solid lipid nanoparticles for the delivery of drug molecules. In: Biomed Mater Eng. 2019; p. 551-76. doi: 10.1016/B978-0-12-818433-2.00016-9
  40. Fan T, Chen C, Guo H, et al. Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur J Pharm Biopharm 2014; 88(2): 518-28. doi: 10.1016/j.ejpb.2014.06.011 PMID: 24968819
  41. Shahgaldian P, Da Silva E, Coleman AW, Rather B, Zaworotko MJ. Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): A detailed study of preparation and stability parameters. Int J Pharm 2003; 253(1-2): 23-38. doi: 10.1016/S0378-5173(02)00639-7 PMID: 12593934
  42. Pople PV, Singh KK. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS PharmSciTech 2006; 7(4): E63-9. doi: 10.1208/pt070491 PMID: 17285742
  43. Youssef NAHA, Kassem AA, Farid RM, Ismail FA. EL-Massik MAE, Boraie NA. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: Preparation, characterization and in vivo evaluation. Int J Pharm 2018; 548(1): 609-24. doi: 10.1016/j.ijpharm.2018.07.014 PMID: 30033394
  44. Agarwal A, Majumder S, Agrawal H, Majumdar SP, Agrawal G. Cationized albumin conjugated solid lipid nanoparticles as vectors for brain delivery of an anti-cancer drug. Curr Nanosci 2011; 7: 71-80. doi: 10.2174/157341311794480291
  45. Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. BioMed Res Int 2014; 2014: 1-37. doi: 10.1155/2014/869269 PMID: 25136634
  46. Yang M, Gu Y, Tang X, Wang T, Liu J. Advancement of lipid-based nanocarriers and combination application with physical penetration technique. Curr Drug Deliv 2019; 16(4): 312-24. doi: 10.2174/1567201816666190118125427 PMID: 30657039
  47. Sabir F, Qindeel M, Rehman A, et al. An efficient approach for development and optimisation of curcumin-loaded solid lipid nanoparticles’ patch for transdermal delivery. J Microencapsul 2021; 38(4): 233-48. doi: 10.1080/02652048.2021.1899321 PMID: 33689550
  48. Lai F, Wissing SA, Müller RH, Fadda AM. Artemisia arborescens L essential oil-loaded solid lipid nanoparticles for potential agricultural application: Preparation and characterization. AAPS PharmSciTech 2006; 7(1): E10-8. doi: 10.1208/pt070102 PMID: 28290017
  49. Vaghasiya H, Kumar A, Sawant K. Development of solid lipid nanoparticles based controlled release system for topical delivery of terbinafine hydrochloride. Eur J Pharm Sci 2013; 49(2): 311-22. doi: 10.1016/j.ejps.2013.03.013 PMID: 23557842
  50. Thakkar H, Kumar Sharma R, Murthy RSR. Enhanced retention of celecoxib-loaded solid lipid nanoparticles after intra-articular administration. Drugs R D 2007; 8(5): 275-85. doi: 10.2165/00126839-200708050-00002 PMID: 17767393
  51. Kaur A, Goindi S, Katare OP. Formulation, characterisation and in vivo evaluation of lipid-based nanocarrier for topical delivery of diflunisal. J Microencapsul 2016; 33(5): 475-86. doi: 10.1080/02652048.2016.1216189 PMID: 27499126
  52. Sahu PK, Mishra DK, Jain N, Rajoriya V, Jain AK. Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel. Drug Dev Ind Pharm 2015; 41(4): 640-9. doi: 10.3109/03639045.2014.891130 PMID: 24564799
  53. Akhlaquer Rahman M, Harwansh R, Aamir Mirza M, Hussain S, Hussain A. Oral lipid based drug delivery system (LBDDS): Formulation, characterization and application: A review. Curr Drug Deliv 2011; 8(4): 330-45. doi: 10.2174/156720111795767906 PMID: 21453264
  54. Padhye SG, Nagarsenker MS. Simvastatin solid lipid nanoparticles for oral delivery: Formulation development and in vivo evaluation. Indian J Pharm Sci 2013; 75(5): 591-8. PMID: 24403661
  55. Silva AC, Kumar A, Wild W, Ferreira D, Santos D, Forbes B. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Int J Pharm 2012; 436(1-2): 798-805. doi: 10.1016/j.ijpharm.2012.07.058 PMID: 22867992
  56. Jawahar N, Reddy G. Nanoparticles: A novel pulmonary drug delivery system for tuberculosis. J Pharm Sci Res 2012; 4: 1901-6.
  57. Mu H, Holm R, Müllertz A. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int J Pharm 2013; 453(1): 215-24. doi: 10.1016/j.ijpharm.2013.03.054 PMID: 23578826
  58. Souto EB, Müller RH. Lipid nanoparticles: Effect on bioavailability and pharmacokinetic changes. In: Schäfer-Korting M, Ed. Drug Deliv. Berlin, Heidelberg: Springer 2010; Vol. 197: pp. 115-41. doi: 10.1007/978-3-642-00477-3_4
  59. Paranjpe M, Müller-Goymann C. Nanoparticle-mediated pulmonary drug delivery: A review. Int J Mol Sci 2014; 15(4): 5852-73. doi: 10.3390/ijms15045852 PMID: 24717409
  60. Weber S, Zimmer A, Pardeike J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art. Eur J Pharm Biopharm 2014; 86(1): 7-22. doi: 10.1016/j.ejpb.2013.08.013 PMID: 24007657
  61. Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PNV, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release 2010; 144(2): 233-41. doi: 10.1016/j.jconrel.2010.02.006 PMID: 20153385
  62. Ellis PP, Riegel M. Prolonged aqueous humor levels of subconjunctival antibiotics after treatment with acetazolamide and/or timolol. Ophthalmic Surg Lasers Imaging Retina 1988; 19(7): 501-5. doi: 10.3928/1542-8877-19880701-10 PMID: 3412761
  63. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002; 238(1-2): 241-5. doi: 10.1016/S0378-5173(02)00080-7 PMID: 11996827
  64. Cavalli R, Morel S, Gasco MR, Chetoni P, Saettone F. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. Int J Pharm 1995; 117(2): 243-6. doi: 10.1016/0378-5173(94)00339-7
  65. Shen J, Deng Y, Jin X, Ping Q, Su Z, Li L. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution. Int J Pharm 2010; 402(1-2): 248-53. doi: 10.1016/j.ijpharm.2010.10.008 PMID: 20934499
  66. Sinha VR, Srivastava S, Goel H, Jindal V. Solid lipid nanoparticles (SLN’s)-Trends and implications in drug targeting. Int J Adv Pharm Sci 2010; 1: 212-38. doi: 10.5138/ijaps.2010.0976.1055.01027
  67. Guimarães KL, Ré MI. Lipid nanoparticles as carriers for cosmetic ingredients: The first (SLN) and the second generation (NLC). In: Nanocosmetics Nanomedicines. Springer 2011; pp. 101-22.
  68. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366(1-2): 170-84. doi: 10.1016/j.ijpharm.2008.10.003 PMID: 18992314
  69. Pardeike J, Müller RH. Coenzyme Q10-loaded NLCs: Preparation, occlusive properties and penetration enhancement. Pharm Technol Eur 2007; 19: 46-9.
  70. Petersen R-D, Hommoss A, Peter M, Muller RH. Nanostructured lipid carrier: A delivery system with protective functions. SÖFW-J 2006; 132: 64-9.
  71. Liu GY, Wang JM, Xia Q. Application of nanostructured lipid carrier in food for the improved bioavailability. Eur Food Res Technol 2012; 234(3): 391-8. doi: 10.1007/s00217-011-1645-z
  72. Weiss J, Decker EA, McClements DJ, Kristbergsson K, Helgason T, Awad T. Solid lipid nanoparticles as delivery systems for bioactive food components. Food Biophys 2008; 3(2): 146-54. doi: 10.1007/s11483-008-9065-8
  73. Lason E, Ogonowski J. Solid lipid nanoparticles–characteristics, application and obtaining. Chemik 2011; 65: 960-7.
  74. Waghmare AS, Grampurohit ND, Gadhave MV, Gaikwad DD, Jadhav SL. Solid lipid nanoparticles: A promising drug delivery system. Int Res J Pharm 2012; 4: 100-7.
  75. Soma D, Attari Z, Reddy MS, Damodaram A, Koteshwara KBG. Solid lipid nanoparticles of irbesartan: Preparation, characterization, optimization and pharmacokinetic studies. Braz J Pharm Sci 2017; 53(1): e15012.
  76. Londhe V. Zaltoprofen loaded solid lipid nanoparticles for topical delivery: Formulation design, in vitro and ex vivo evaluation. MOJ Bioequivalence Bioavailability 2017; 4(2) doi: 10.15406/mojbb.2017.04.00065
  77. Gardouh A. Design and characterization of glyceryl monostearate solid lipid nanoparticles prepared by high shear homogenization. Br J Pharm Res 2013; 3(3): 326-46. doi: 10.9734/BJPR/2013/2770
  78. Beniwal A, Choudhary H. Rosuvastatin calcium-loaded Solid Lipid Nanoparticles (SLN) using design of experiment approach for oral delivery. Int J Chem Biol 2017; 6(5): 2029. doi: 10.21746/ijcls.2017.5.1
  79. Nandini PT, Doijad RC, Shivakumar HN, Dandagi PM. Formulation and evaluation of gemcitabine-loaded solid lipid nanoparticles. Drug Deliv 2015; 22(5): 647-51. doi: 10.3109/10717544.2013.860502 PMID: 24283392
  80. Khalil RM, Abd El-Bary A, Kassem MA, Ghorab MM, Ahmed MB. Solid lipid nanoparticles for topical delivery of meloxicam: Development and in vitro characterization. Eur Sci J 2013; 9: 24-6.
  81. Palei NNN, Das MK. Preparation and characterization of lornoxicam loaded solid lipid nanoparticles made from different lipids. Int J Pharm Pharm Sci 2013; 5: 438-42.
  82. Verma S, Kumar A, Malik V, Kumar V. Compritrol ATO 888 based solid lipid nanoparticles of cefixime: Formulation and evaluation. Der Pharmacia Sinica 2013; 4: 8-13.
  83. Jain S, Mistry MA, Swarnakar NK. Enhanced dermal delivery of acyclovir using solid lipid nanoparticles. Drug Deliv Transl Res 2011; 1(5): 395-406. doi: 10.1007/s13346-011-0036-0 PMID: 25788423
  84. Gupta M, Vyas SP. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem Phys Lipids 2012; 165(4): 454-61. doi: 10.1016/j.chemphyslip.2012.01.006 PMID: 22309657
  85. Jia L, Zhang D, Li Z, et al. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloids Surf B Biointerfaces 2010; 80(2): 213-8. doi: 10.1016/j.colsurfb.2010.06.008 PMID: 20621458
  86. Chen-yu G, Chun-fen Y, Qi-lu L, et al. Development of a Quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int J Pharm 2012; 430(1-2): 292-8. doi: 10.1016/j.ijpharm.2012.03.042 PMID: 22486962
  87. Gokce E, Korkmaz E, Dellera E, Sandri G, Bonferoni MC, Ozer O. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: Evaluation of antioxidant potential for dermal applications. Int J Nanomedicine 2012; 7: 1841-50. doi: 10.2147/IJN.S29710 PMID: 22605933
  88. Pardeike J, Weber S, Haber T, et al. Development of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm 2011; 419(1-2): 329-38. doi: 10.1016/j.ijpharm.2011.07.040 PMID: 21839157
  89. Souza LG, Silva EJ, Martins ALL, et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm 2011; 79(1): 189-96. doi: 10.1016/j.ejpb.2011.02.012 PMID: 21352915
  90. Nayak AP, Tiyaboonchai W, Patankar S, Madhusudhan B, Souto EB. Curcuminoids-loaded lipid nanoparticles: Novel approach towards malaria treatment. Colloids Surf B Biointerfaces 2010; 81(1): 263-73. doi: 10.1016/j.colsurfb.2010.07.020 PMID: 20688493
  91. Pathak P, Nagarsenker M. Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery. AAPS PharmSciTech 2009; 10(3): 985-92. doi: 10.1208/s12249-009-9287-1 PMID: 19641997
  92. Zhang X, Liu J, Qiao H, et al. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol 2010; 197(1-2): 120-8. doi: 10.1016/j.powtec.2009.09.004
  93. Shah RM, Malherbe F, Eldridge D, Palombo EA, Harding IH. Physicochemical characterization of solid lipid nanoparticles (SLNs) prepared by a novel microemulsion technique. J Colloid Interface Sci 2014; 428: 286-94. doi: 10.1016/j.jcis.2014.04.057 PMID: 24910064

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers